FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
You may also be interested in...
Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study
US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.
FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority
Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.
FDA Closes 2013 With Flurry Of Citations For Misleading Rx Promotions
Office of Prescription Drug Promotion issues 23 letters in 2013, five less than the previous year.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: